

CANCER DISCOVERY

CONTENTS

JULY 2011 ■ VOLUME 1 ■ NUMBER 2

IN THIS ISSUE Highlighted research articles x

NEWS IN BRIEF Important news stories affecting the community 92

NEWS IN DEPTH Drug Discovery Gets an Academic Push 93

RESEARCH WATCH Selected highlights of recent articles of exceptional significance from the cancer literature 96

VIEWS In The Spotlight

New Insight Puts CRAF in Sight as a Therapeutic Target 98

A. P. Rebocho and R. Marais

Commentary on Karreth et al., p. 128

The First Line of Intra-abdominal Metastatic Attack: Breaching the Mesothelial Cell Layer 100

H. A. Kenny, K. M. Nieman, A. K. Mitra, and E. Lengyel

Commentary on Iwanicki et al., p. 144

Kras, Pten, NF- κ B, and Inflammation: Dangerous Liaisons 103

P. J. Chiao and J. Ling

Commentary on Ying et al., p. 158

New Routes to Old Places: PIK3R1 and PIK3R2 Join PIK3CA and PTEN as Endometrial Cancer Genes 106

S. Herrero-Gonzalez and A. Di Cristofano

Commentary on Cheung et al., p. 170

Prospective

The APL Paradigm and the "Co-Clinical Trial" Project 108

C. Nardella, A. Lunardi, A. Patnaik, L. C. Cantley, and P. P. Pandolfi

REVIEW The Drug-Induced Degradation of Oncoproteins: An Unexpected Achilles' Heel of Cancer Cells? 117

J. Ablain, R. Nasr, A. Bazarbachi, and H. de Thé

RESEARCH BRIEF C-Raf Is Required for the Initiation of Lung Cancer by K-Ras^{G12D} 128



F. A. Karreth, K. K. Frese, G. M. DeNicola, M. Baccarini, and D. A. Tuveson

Précis: C-Raf, but not B-Raf, is required for K-Ras^{G12D}-induced tumorigenesis and should be considered an important therapeutic target.

Temporal Dissection of Tumorigenesis in Primary Cancers 137

S. Durinck, C. Ho, N. J. Wang, W. Liao, L. R. Jakkula, E. A. Collisson, J. Pons, S-W. Chan, E. T. Lam, C. Chu, K. Park, S-W. Hong, J. S. Hur, N. Huh, I. M. Neuhaus, S. S. Yu, R. C. Grekin, T. M. Mauro, J. E. Cleaver, P-Y. Kwok, P. E. LeBoit, G. Getz, K. Cibulskis, J. C. Aster, H. Huang, E. Purdom, J. Li, L. Bolund, S. T. Arron, J. W. Gray, P. T. Spellman, and R. J. Cho

Précis: Next-generation sequencing is used to temporally order the occurrence of genetic aberrations in epithelial cancer.





RESEARCH ARTICLES

Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium.....144



M. P. Iwanicki, R. A. Davidowitz,
M. R. Ng, A. Besser, T. Muranen,
M. Merritt, G. Danuser, T. Ince, and J. S. Brugge

Précis: Time-lapse video microscopy shows that ovarian cancer spheroids clear the mesothelium via myosin-generated force.

PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB-Cytokine Network158

H. Ying, K. G. Elpek, A. Vinjamoori,
S. M. Zimmerman, G. C. Chu, H. Yan,
E. Fletcher-Sananikone, H. Zhang, Y. Liu,
W. Wang, X. Ren, H. Zheng, A. C. Kimmelman,
J-H. Paik, C. Lim, S. R. Perry, S. Jiang, B. Malinn,
A. Protopopov, S. Colla, Y. Xiao, A. F. Hezel,
N. Bardeesy, S. J. Turley, Y. A. Wang, L. Chin,
S. P. Thayer, and R. A. DePinho

Précis: PTEN is shown to be a tumor suppressor in human PDAC and controls NF-κB-dependent transcription via PI3K-AKT signaling.

High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability170



L. W. T. Cheung, B. T. Hennessy, J. Li,
S. Yu, A. P. Myers, B. Djordjevic, Y. Lu,
K. Stemke-Hale, M. D. Dyer, F. Zhang, Z. Ju,
L. C. Cantley, S. E. Scherer, H. Liang, K. H. Lu,
R. R. Broaddus, and G. B. Mills

Précis: High frequency of mutations in endometrioid endometrial cancers leads to PI3K pathway activation.

ON THE COVER

Cheung and colleagues report aberrations in the PI3K pathway occur in a majority of endometrioid endometrial cancers, with coordinate mutations of multiple pathway members being more common than predicted by chance. Multiple gain-of-function PIK3R1 and PIK3R2 mutations result in the stabilization of PTEN protein with likely contribution from the ubiquitin-proteasome degradative pathway, as depicted by the cover. For details, please see the article by Cheung and colleagues on page 158.

